

Federal government releases supply of Tamiflu[®] (oseltamivir) from national stockpile to address shortage.

- The <u>U.S. Department of Health & Human Services</u> (HHS) has been tracking the increased demand and resulting shortage of <u>Tamiflu (oseltamivir</u>) during this winter season. To ease the shortage of drug, HHS is giving local U.S. jurisdictions access to additional supplies of Tamiflu in the government-sponsored Strategic National Stockpile (SNS).
- Jurisdictions may access additional supplies in the following ways:
 - Jurisdictions can dispense certain lots of Tamiflu 30 mg, 45 mg and 75 mg that were procured for pandemic preparedness under the HHS Antiviral Subsidy Vendor Contract between 2006 - 2009. These supplies may be held in jurisdictional stockpile for pandemic use but are now allowed for use in the current flu season.
 - Jurisdictions that have exhausted their own stockpiled supplies of Tamiflu may request supplemental Tamiflu 75 mg from the SNS. This product is part of the federal stockpile of antiviral drugs held for pandemic preparedness.
- The Tamiflu products held in jurisdictional stockpiles and in the SNS for pandemic use include drug lots that have been extended by the FDA for up to 20 years beyond their original manufacture date, provided they have been stored under labeled storage conditions. These lots have not been relabeled with new expirations, and healthcare providers and recipients should be notified of the 20-year extension.
- Refer to the <u>press release</u> for more information on how jurisdictions can request Tamiflu through the SNS.
- The supply of generic Tamilfu is also being monitored by the FDA and American Society of Health-System Pharmacists (ASHP), who are working closely to share drug supply information.
- Although oseltamivir has experienced some <u>supply disruptions</u>, <u>product is available</u> from both brand and generic manufacturers. However, there may be periodic local outages of product in retail. Supply of other antiviral medications, including <u>Relenza[®] (zanamivir)</u> and <u>Xofluza[®]</u> (<u>baloxavir marboxil</u>) are available. Some manufacturers report that more supply of oseltamivir will be available late-December 2022.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.